A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
Clinical trial NCT01846416 · COMPLETED
Trial details
- NCT number
- NCT01846416
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-05-30
- Primary completion
- 2015-01-07
- Enrollment
- 138
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.